# Sotera Health Co: financial statements, quarterly

SHC · Nasdaq · CIK 1822479 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/shc.md) · [Financials](/companies/shc/financials.md) · [Filings](/companies/shc/filings.md) · [Insiders](/companies/shc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/shc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [263](/filings/0001822479-24-000049.md) | [310 d](/filings/0001822479-26-000015.md) | [248](/filings/0001822479-25-000025.md) | [277](/filings/0001822479-25-000044.md) | [285](/filings/0001822479-25-000054.md) | [290 d](/filings/0001822479-26-000015.md) | [255](/filings/0001822479-26-000031.md) | [294](/filings/0001822479-26-000047.md) | [311](/filings/0001822479-25-000054.md) | [303 d](/filings/0001822479-26-000015.md) | [280](/filings/0001822479-26-000031.md) | [321](/filings/0001822479-26-000047.md) |
| Cost of revenue | $m | [117](/filings/0001822479-24-000049.md) | [130 d](/filings/0001822479-26-000015.md) | [121](/filings/0001822479-25-000025.md) | [124](/filings/0001822479-25-000044.md) | [127](/filings/0001822479-25-000054.md) | [126 d](/filings/0001822479-26-000015.md) | [119](/filings/0001822479-26-000031.md) | [128](/filings/0001822479-26-000047.md) | [134](/filings/0001822479-25-000054.md) | [138 d](/filings/0001822479-26-000015.md) | [133](/filings/0001822479-26-000031.md) | [143](/filings/0001822479-26-000047.md) |
| Gross profit | $m | [146](/filings/0001822479-24-000049.md) | [180 d](/filings/0001822479-26-000015.md) | [127](/filings/0001822479-25-000025.md) | [153](/filings/0001822479-25-000044.md) | [158](/filings/0001822479-25-000054.md) | [164 d](/filings/0001822479-26-000015.md) | [135](/filings/0001822479-26-000031.md) | [167](/filings/0001822479-26-000047.md) | [178](/filings/0001822479-25-000054.md) | [166 d](/filings/0001822479-26-000015.md) | [147](/filings/0001822479-26-000031.md) | [178](/filings/0001822479-26-000047.md) |
| Selling, general and administrative | $m | [54.1](/filings/0001822479-24-000049.md) | [60.4 d](/filings/0001822479-26-000015.md) | [58.2](/filings/0001822479-25-000025.md) | [60.6](/filings/0001822479-25-000044.md) | [62.0](/filings/0001822479-25-000054.md) | [61.8 d](/filings/0001822479-26-000015.md) | [63.1](/filings/0001822479-26-000031.md) | [68.9](/filings/0001822479-26-000047.md) | [63.3](/filings/0001822479-25-000054.md) | [57.5 d](/filings/0001822479-26-000015.md) | [68.2](/filings/0001822479-26-000031.md) | [68.2](/filings/0001822479-26-000047.md) |
| Operating income | $m | [76.1](/filings/0001822479-24-000049.md) | [104 d](/filings/0001822479-25-000015.md) | [53.2](/filings/0001822479-24-000020.md) | [76.8](/filings/0001822479-24-000041.md) | [80.5](/filings/0001822479-24-000049.md) | [87.1 d](/filings/0001822479-25-000015.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [14.1](/filings/0001822479-24-000049.md) | [27.0 d](/filings/0001822479-26-000015.md) | [4.7](/filings/0001822479-25-000025.md) | [6.4](/filings/0001822479-25-000044.md) | [25.8](/filings/0001822479-25-000054.md) | [32.6 d](/filings/0001822479-26-000015.md) | [(1.6)](/filings/0001822479-26-000031.md) | [10.9](/filings/0001822479-26-000047.md) | [24.5](/filings/0001822479-25-000054.md) | [35.7 d](/filings/0001822479-26-000015.md) | [16.0](/filings/0001822479-26-000031.md) | [24.4](/filings/0001822479-26-000047.md) |
| Net income | $m | [(13.7)](/filings/0001822479-24-000049.md) | [38.7 d](/filings/0001822479-26-000015.md) | [6.3](/filings/0001822479-25-000025.md) | [8.8](/filings/0001822479-25-000044.md) | [17.0](/filings/0001822479-25-000054.md) | [12.3 d](/filings/0001822479-26-000015.md) | [(13.3)](/filings/0001822479-26-000031.md) | [8.0](/filings/0001822479-26-000047.md) | [48.4](/filings/0001822479-25-000054.md) | [34.8 d](/filings/0001822479-26-000015.md) | [26.6](/filings/0001822479-26-000031.md) | [53.6](/filings/0001822479-26-000047.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001822479-24-000049.md) | not reported | [0.02](/filings/0001822479-25-000025.md) | [0.03](/filings/0001822479-25-000044.md) | [0.06](/filings/0001822479-25-000054.md) | not reported | [(0.05)](/filings/0001822479-26-000031.md) | [0.03](/filings/0001822479-26-000047.md) | [0.17](/filings/0001822479-25-000054.md) | not reported | [0.09](/filings/0001822479-26-000031.md) | [0.19](/filings/0001822479-26-000047.md) |
| Basic EPS | $ per share | [(0.05)](/filings/0001822479-24-000049.md) | not reported | [0.02](/filings/0001822479-25-000025.md) | [0.03](/filings/0001822479-25-000044.md) | [0.06](/filings/0001822479-25-000054.md) | not reported | [(0.05)](/filings/0001822479-26-000031.md) | [0.03](/filings/0001822479-26-000047.md) | [0.17](/filings/0001822479-25-000054.md) | not reported | [0.09](/filings/0001822479-26-000031.md) | [0.19](/filings/0001822479-26-000047.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [245](/filings/0001822479-23-000063.md) | [296](/filings/0001822479-25-000015.md) | [261](/filings/0001822479-24-000020.md) | [246](/filings/0001822479-24-000041.md) | [307](/filings/0001822479-24-000049.md) | [277](/filings/0001822479-26-000015.md) | [304](/filings/0001822479-25-000025.md) | [332](/filings/0001822479-25-000044.md) | [299](/filings/0001822479-25-000054.md) | [345](/filings/0001822479-26-000047.md) | [314](/filings/0001822479-26-000031.md) | [357](/filings/0001822479-26-000047.md) |
| Current assets | $m | [520](/filings/0001822479-23-000063.md) | [557](/filings/0001822479-25-000015.md) | [487](/filings/0001822479-24-000020.md) | [498](/filings/0001822479-24-000041.md) | [564](/filings/0001822479-24-000049.md) | [526](/filings/0001822479-26-000015.md) | [555](/filings/0001822479-25-000025.md) | [608](/filings/0001822479-25-000044.md) | [578](/filings/0001822479-25-000054.md) | [613](/filings/0001822479-26-000047.md) | [586](/filings/0001822479-26-000031.md) | [646](/filings/0001822479-26-000047.md) |
| Total assets | $m | [3,037](/filings/0001822479-23-000063.md) | [3,130](/filings/0001822479-25-000015.md) | [3,060](/filings/0001822479-24-000020.md) | [3,058](/filings/0001822479-24-000041.md) | [3,149](/filings/0001822479-24-000049.md) | [3,072](/filings/0001822479-26-000015.md) | [3,098](/filings/0001822479-25-000025.md) | [3,217](/filings/0001822479-25-000044.md) | [3,186](/filings/0001822479-25-000054.md) | [3,263](/filings/0001822479-26-000047.md) | [3,236](/filings/0001822479-26-000031.md) | [3,307](/filings/0001822479-26-000047.md) |
| Current liabilities | $m | [201](/filings/0001822479-23-000063.md) | [231](/filings/0001822479-25-000015.md) | [152](/filings/0001822479-24-000020.md) | [170](/filings/0001822479-24-000041.md) | [196](/filings/0001822479-24-000049.md) | [191](/filings/0001822479-26-000015.md) | [226](/filings/0001822479-25-000025.md) | [246](/filings/0001822479-25-000044.md) | [242](/filings/0001822479-25-000054.md) | [250](/filings/0001822479-26-000047.md) | [208](/filings/0001822479-26-000031.md) | [231](/filings/0001822479-26-000047.md) |
| Total liabilities | $m | [2,659](/filings/0001822479-23-000063.md) | [2,687](/filings/0001822479-25-000015.md) | [2,630](/filings/0001822479-24-000020.md) | [2,635](/filings/0001822479-24-000041.md) | [2,679](/filings/0001822479-24-000049.md) | [2,667](/filings/0001822479-26-000015.md) | [2,683](/filings/0001822479-25-000025.md) | [2,705](/filings/0001822479-25-000044.md) | [2,636](/filings/0001822479-25-000054.md) | [2,657](/filings/0001822479-26-000047.md) | [2,613](/filings/0001822479-26-000031.md) | [2,641](/filings/0001822479-26-000047.md) |
| Long-term debt | $m | [2,223](/filings/0001822479-23-000063.md) | [2,224](/filings/0001822479-25-000015.md) | [2,225](/filings/0001822479-24-000020.md) | [2,214](/filings/0001822479-24-000041.md) | [2,211](/filings/0001822479-24-000049.md) | [2,208](/filings/0001822479-26-000015.md) | [2,205](/filings/0001822479-25-000025.md) | [2,203](/filings/0001822479-25-000044.md) | [2,129](/filings/0001822479-25-000054.md) | [2,127](/filings/0001822479-26-000047.md) | [2,124](/filings/0001822479-26-000031.md) | [2,126](/filings/0001822479-26-000047.md) |
| Current portion of debt | $m | [5.2](/filings/0001822479-23-000063.md) | [4.8](/filings/0001822479-25-000015.md) | [4.8](/filings/0001822479-24-000020.md) | [11.1](/filings/0001822479-24-000041.md) | [14.8](/filings/0001822479-24-000049.md) | [14.8](/filings/0001822479-26-000015.md) | [14.8](/filings/0001822479-25-000025.md) | [14.8](/filings/0001822479-25-000044.md) | [14.0](/filings/0001822479-25-000054.md) | [14.0](/filings/0001822479-26-000047.md) | [14.0](/filings/0001822479-26-000031.md) | [13.9](/filings/0001822479-26-000047.md) |
| Shareholders' equity | $m | [377](/filings/0001822479-24-000049.md) | [444](/filings/0001822479-26-000015.md) | [429](/filings/0001822479-25-000044.md) | [423](/filings/0001822479-25-000054.md) | [470](/filings/0001822479-25-000054.md) | [405](/filings/0001822479-26-000047.md) | [414](/filings/0001822479-26-000047.md) | [511](/filings/0001822479-26-000047.md) | [550](/filings/0001822479-25-000054.md) | [606](/filings/0001822479-26-000047.md) | [623](/filings/0001822479-26-000047.md) | [666](/filings/0001822479-26-000047.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [41.8 d](/filings/0001822479-24-000049.md) | [113 d](/filings/0001822479-26-000015.md) | [9.7](/filings/0001822479-25-000025.md) | [61.3 d](/filings/0001822479-25-000044.md) | [97.5 d](/filings/0001822479-25-000054.md) | [55.7 d](/filings/0001822479-26-000015.md) | [55.5](/filings/0001822479-26-000031.md) | [57.4 d](/filings/0001822479-26-000047.md) | [71.2 d](/filings/0001822479-25-000054.md) | [103 d](/filings/0001822479-26-000015.md) | [29.4](/filings/0001822479-26-000031.md) | [88.5 d](/filings/0001822479-26-000047.md) |
| Capital expenditure | $m | [52.0 d](/filings/0001822479-24-000049.md) | [64.8 d](/filings/0001822479-26-000015.md) | [34.9](/filings/0001822479-25-000025.md) | [41.9 d](/filings/0001822479-25-000044.md) | [36.4 d](/filings/0001822479-25-000054.md) | [65.9 d](/filings/0001822479-26-000015.md) | [19.9](/filings/0001822479-26-000031.md) | [31.2 d](/filings/0001822479-26-000047.md) | [36.2 d](/filings/0001822479-25-000054.md) | [50.7 d](/filings/0001822479-26-000015.md) | [46.2](/filings/0001822479-26-000031.md) | [46.4 d](/filings/0001822479-26-000047.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [280](/filings/0001822479-23-000063.md) | [283](/filings/0001822479-24-000020.md) | [283](/filings/0001822479-24-000041.md) | [281](/filings/0001822479-24-000049.md) | [284](/filings/0001822479-25-000025.md) | [285](/filings/0001822479-25-000044.md) | [286](/filings/0001822479-25-000054.md) | [284](/filings/0001822479-26-000031.md) | [286](/filings/0001822479-26-000047.md) | [287](/filings/0001822479-25-000054.md) | [288](/filings/0001822479-26-000031.md) | [288](/filings/0001822479-26-000047.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 285,374,795 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001822479-26-000047.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.